Beijing Airdoc expects H1 net loss up to RMB 50 million, swings from profit a year earlier

• Beijing Airdoc forecast net loss of no more than RMB 50 million for the six months ended June 30, 2026.
• Compares with net profit of about RMB 0.44 million in the year-earlier period.
• Loss outlook driven by higher R&D, computing power, data governance spending for “WanYu” medical LLM, AI Agents, clinical trials.
• Myopia prevention business in expansion phase, lifting marketing, medical services, store deployment costs ahead of revenue scale benefits.
• Exchange-rate moves also weighed; organizational restructuring aimed to cut costs, improve efficiency, partly offsetting the hit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Airdoc Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294758), on August 21, 2026, and is solely responsible for the information contained therein.